SELLAS Life Sciences Group, Inc.: basic earnings per share

What this measure means

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Exact concept: us-gaap:EarningsPerShareBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Reading these values

This selected numerical history matches Diluted earnings per share for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

SELLAS Life Sciences' 2024 and 2025 statements display dollars in thousands but full share counts and unscaled EPS. Basic weighted-average shares already include prefunded warrants and shares held in abeyance because delivery requires only nominal consideration. Other potential shares from warrants, options and unvested restricted stock are excluded as anti-dilutive during losses, so basic and diluted loss EPS are equal. The excluded-securities table uses thousands; its amounts are not additions to the reported weighted-average denominator. Read the source filing.

Selected filing history

Related financial histories

• SELLAS Life Sciences Group, Inc.: total assets
• SELLAS Life Sciences Group, Inc.: total liabilities
• SELLAS Life Sciences Group, Inc.: stockholders equity
• SELLAS Life Sciences Group, Inc.: cash and cash equivalents
• SELLAS Life Sciences Group, Inc.: net income or loss
• SELLAS Life Sciences Group, Inc.: operating cash flow
• SELLAS Life Sciences Group, Inc.: capital expenditure payments
• SELLAS Life Sciences Group, Inc.: contract revenue excluding tax
• SELLAS Life Sciences Group, Inc.: financing cash flow
• SELLAS Life Sciences Group, Inc.: investing cash flow
• SELLAS Life Sciences Group, Inc.: retained earnings or deficit
• SELLAS Life Sciences Group, Inc.: basic weighted-average shares
• SELLAS Life Sciences Group, Inc.: diluted weighted-average shares
• SELLAS Life Sciences Group, Inc.: diluted earnings per share
• SELLAS Life Sciences Group, Inc.: income tax expense or benefit
• SELLAS Life Sciences Group, Inc.: net property, plant and equipment
• SELLAS Life Sciences Group, Inc.: share-based compensation expense
• SELLAS Life Sciences Group, Inc.: operating income or loss
• SELLAS Life Sciences Group, Inc.: current assets
• SELLAS Life Sciences Group, Inc.: current liabilities
• SELLAS Life Sciences Group, Inc.: current accounts payable
• SELLAS Life Sciences Group, Inc.: goodwill carrying amount
• SELLAS Life Sciences Group, Inc.: net current accounts receivable
• SELLAS Life Sciences Group, Inc.: operating expenses
• SELLAS Life Sciences Group, Inc.: net inventory
• SELLAS Life Sciences Group, Inc.: cost of revenue
• SELLAS Life Sciences Group, Inc.: selling, general and administrative expense
• SELLAS Life Sciences Group, Inc.: research and development expense

Inspect the source

Entity

SELLAS Life Sciences Group, Inc. / CIK 0001390478

Captured

2026-09-20T07:59:20.955Z

SEC response SHA-256

818666353c7435e791daaef96b770961681bfce07618c1566e0bf1f54ce09cc0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001390478.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))